Alkilleyici Ajanların Etki Mekanızmaları ve Sınıflandırılması
Özet
Alkilleyici ajanlar, tıp literatüründe klinik olarak anlamlı antitümör aktivite gösteren ilk hormonal olmayan kemoterapötik bileşiklerdir. Birinci Dünya Savaşı'nda hardal gazına maruz kalan kurbanlarda hematopoietik ve lenfoid sistemlerin baskılanmasının gözlenmesiyle temeli atılan bu ajanlar, zamanla daha az toksik türevlerin geliştirilmesiyle kanser tedavisinin vazgeçilmez bir parçası haline gelmiştir. Sitotoksik etkilerini, hücrelerdeki elektronca zengin atomlarla, özellikle de DNA bazlarıyla kovalent bağlar kurarak (alkilleme) gösterirler. Monofonksiyonel ajanlar tek bir DNA dizisine bağlanırken, bifonksiyonel ajanlar DNA çift sarmalında çapraz bağlar oluşturarak hücre çoğalmasını güçlü bir şekilde engeller. Klinik pratiklerine göre azot hardalları (siklofosfamid, ifosfamid, melfalan, klorambusil), aziridinler (tiotepa, mitomisin C), alkil sülfonatlar (busulfan), nitrozoüreler (BCNU, CCNU) ile hidrazin ve triazin türevleri (prokarbazin, dakarbazin, temozolomid) gibi farklı alt sınıflara ayrılırlar. Bu ilaçların farmakokinetik özellikleri, doku duyarlılıkları ve doz sınırlayıcı toksisiteleri (kardiyak hasar, hemorajik sistit veya miyeloablasyon gibi) moleküler yapılarına ve hücre içi metabolizma mekanizmalarına bağlı olarak değişkenlik göstermektedir.
Alkylating agents are the first non-hormonal chemotherapeutic compounds to demonstrate clinically significant antitumor activity in medical literature. Pioneered by the observation of hematopoietic and lymphoid system depression in victims exposed to sulfur mustard gas during World War I, these agents have become an indispensable part of cancer treatment through the development of less toxic derivatives. They exert their cytotoxic effects by reacting with electron-rich atoms in cells, particularly DNA bases, to form covalent bonds (alkylation). While monofunctional agents bind to a single DNA sequence, bifunctional agents generate interstrand cross-links within the DNA double helix, effectively preventing cellular replication. In clinical practice, they are classified into distinct subcategories such as nitrogen mustards (cyclophosphamide, ifosfamide, melphalan, chlorambucil), aziridines (thiotepa, mitomycin C), alkyl sulfonates (busulfan), nitrosoureas (BCNU, CCNU), and hydrazine/triazine derivatives (procarbazine, dacarbazine, temozolomide). The pharmacokinetic properties, tissue specificities, and dose-limiting toxicities (such as cardiac damage, hemorrhagic cystitis, or myeloablation) of these drugs vary significantly depending on their molecular structures and intracellular metabolic pathways.
Referanslar
Rhodes R. Themaking of theatomicbomb. New YO'L: Simon &Schuster, 1986.
Adair CPI, Bogg I l]. Experilnentalandclinicalstudies of thetreatment of cancerbydichloroethylsulfide (nurstavdgas). Ann Surg1931 ;93:190.
Rhoads C. NitrogenInustards in treatment of neoplasticdisease. JAMA 1946; 131:6568.
Coodrnan IS, MM, Dameshek W, et al. Use of methyl-bis(beta-chlorethyl)amine hydrochloridefor I lodgkin'sdisease, lymphosarcoma, leukemia. JAMA 1946; 132: 126
Jacobson LP, Spurr C, Barron E, et al. Studies of theeffect of methyl-bis(beta-chloroethyl)amine hydrochloride on neoplasticdiseasesandallieddisorders of thehematopoieticsystem. JAMA 1946;132:263.
DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in thetreatment of advancedHodgkin'sdisease. Ann InternMed 1970;73(6) :881.
MillardJT, Raucher S, Hopkins PB. Mechlorethaminecrosslinksdeoxyguanosine residues at5’ GNC sequences in duplex DNA sequences in duplex DNA fragments. J AmChemSoc1990;112:2459
Brookes P, Lawley PD. Thereaction of mono- anddifunctionalalkylatingagentswithnucleicacids. Biochem j 1961;80:486
Dong Q, Barsky D, Colvin ME, et al. A structuralbasisfor a phosphoramidemustard-induced DNA interstrandcross-link at (GAC). ProcNatlAcadSci US A 1995;92 (26) : 12170.
Fisher B, S, Wickerham DL, et al. Increasedintensificationand total dose of cyclophosphamide in a doxorubicin-cyclophosphamideregimenforthetreatment of primarybreastcancer: findings from National Surgical Adjuvant Breast and Bowel Project W22.JC1in Oncol 1997;15(5):1858
Falkson G, Tormey DC, Carey P, Witte R, Falkson HC. Long-termsurvival of patients treated with combination chemotherapy for metastatic breast cancer. EurJCancer1991 :973.
DeVita VT Jr, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffusehistiocvticlymphoma, a potentiallycurabledisease. Lancet 1975; 1:248.
Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effectiveandwell-toleratedregimen in poor-risk, aggressivenon-Hodgkin'slymphoma. Blood 1990;76(7):1293
Carpenter PA, White L, McCowageCull, et al. A dose-intensive, cyclophosphanride-based regimen for the treatment of recurrent/progressive or advanced solidtcuuots of childhood—a reportfromtheAustraliaand New ZealandChil(lxvn'sCancerStudyGroup. Cancer 1997;80(3):489
McCowage G, Tien R, McLendon R, ec al. Successfulcreatuuent of childhoodpilocyticastrocytomasmetastaticco (he leptojneningeswithhiglHIosecyclophosphamide. Med Pediatr Oncol 1996;27(1):32.
Colvin 0M. Drugresistance in thetreatjnenC of sarconras. Semin Oncol 1997;24(5):580
Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N EnglJMed 1983;309(22):1347
Blazar BR, Rarnsay NK, KerscyJII, ct al. Pretransplant conditioning with busulfan (Myle_ ran) andcyclopho«phamiclefornomnalignantdiseases. Assessment of engraftment fol_ histocc»npatibleallogeneic bone marrowtransplantation. Transplantation 1985;39(6):597.
Antman K, Ayash L, Elias A, et al. High-dosecyclophosphamide, thiotepa, and platin autologousmarrowsupport in womenwithmeasurableadvancedbreast can_ cer respondingtostandarddosetherapy: analysisby age. J NatlCancerInstMonogr 1994;16:91
Ferrara F, Copia C, Annunziata M, et al. Complete remission of refractoryanemiafollowing a singlehighdose of cyclophosphamide. Ann Hematol 1999;78(2) :87.
Brodsky RA, Petri M, Smith BD, et al. Immunoablativehigh-dosecyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann InternMed 1998;129(12):1031
Colvin M, Hilton J. Pharmacology of cyclophosphamideandmetabolites. CancerTreatRep1981;3:89
Colvin M, Padgett CA, Fenselau C. A biologicallyactive metabolite of cyclophosphamide. CancarRes 1973;33(4):915
Colvin M, Brundrett RB, Kan MN, Jardine I, Fenselau C. Alkylatingproperties of phoyphoramidemustard. CancerRes 1976;36(3):1121.
Gamcsik MP, Ludeman SM, Shulman-Roskes EM, et al. Protonation of phosphoramide mustard and other phosphoramides. JMedChem 1993;36(23) :3636.
Hilton J. Deoxyribonucleicacidcross-linkingby 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitiveand -resistant L1210 cells. BiochemPhannacol 1984;33(12):1867
Shulman-Roskes EM, NoeDA,Gamcsik MP, et al. The partitioning of phusphoramidetard and its aziridinium ions among alkylation and P-N bondhydrolysisreactions. J MedChem 1998;41(4):515
Hilton J. Role of aldehydedehydrogenase in cyclophosphamide-resistant L1210 leukemia. CancerRes 1984;44(11):5156
Russo JE, Hilton J. Characterization of cytosolic aldehyde dehydrogenase from phosphamide resistant 1.1210 cells. CancerRes 1988;48(11):2963
Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevatedaldehydedehydrogenase in humanhematopoieticprogenitorcells. Blood 1990;75(10):1947
Russo JE, Hilton J, Colvin 0M. The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. ProgClinBiolRes1989;290:65
Nissen-veyer R, Host H. A comparison between the hematological side effects of cyclo_ phosphamide and nitrogenmustard. CancerChemotherRep1960;9:51
Mullins GM, Colvin M. Intensivecyclophosphamide (NSC-26271) therapy for solid tumors. CancerChemotherRep 1975;59(2) :411.
Dong Q, Bullock N, Aliosman F, et al. Repairanalysis of 4-hydroperoxycyclophosphamide induced DNA interstrandcross-linking in the C-Myc gene in 4-hydroperoxycvclophosphamide-sensitive and -resistant medulloblastomacelllines. CancerChemotherPharmacol 1996;37(3):242.
Gamcsik MP, Millis KK, Colvin M. Noninvasivedetection of elevatedglutathionelevels in Mcf-7 cellsresistantto 4-hydroperoxycyclophosphamide. CancerRes 1995;55(10):2012
Rowley SD, Jones RJ, Piantadosi S, et al. Efficacy of exvivopurgingforautologous bone marrowtransplantation in thetreatment of acutenonlymphoblasticleukemia. Blood 1989;74(1):501
BakkeJE, Feil VJ, Fjelstul CE, Thacker EJ. Metabolism of cyclophosphamidebysheep.JAgrıcfoodchem 1972;20(2):384
Jardine J, Fenselau C, Appler M, et al. Quantitationbygaschromatographv-chetnicalioniE'FtjonInassspectrometry of cyclophosphamide, phosphoramidemustard, andnomiuogenmustard in theplasrnaandurine of patientsreceivingcyclophosphamidetherapy. Cancer RES 1978;38(2):408
Chen TL, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cycloph0&phamideand in patients with metastaåC breast cancer receiving hig)Hlosecljejnochevapy followed by autologous bone marrow transplantation. I)tug Metal) Dispos 1997;25 (5) :544.
Ren S, Kalhorn TF, McDonald Gil, et al. Pharnvacokinetics of cyclophosphamideanditsmetabolites in bone marrow transplantation patients. ClinPhannacolTher 1998;64(3):289
Phillips FS, Sternberg SS, Cronin AP, PM Cyclophosphamide and urinary bladdericity. CancerRes 1961;21:1577
Forni AM, Koss LG, Gcllcv W. Cytologicalstudy of the effect of cyclophosphamide on theepitheliunl of thcurinarybladder in InaneCancer 1964; 17:1348.
Cox PJ. Cvclophospharnidecystitis—identification of acrolein as thecausativeagent. Biochempharmacol 1979;28(13):2045
DeFronzo RX, Braine H, Colvin M, Davis PJ. Waterintoxication in manaftercyclophosphamidetherapy. Time courseandrelationtodrugactivation. Ann InternMed 1973;78(6):861.
Harlow PJ, DeClerck YA, Shore NA, et al. A fatal case of inappropriate ADH secretion induced by cyclophosphamidetherapy. Cancer 1979;44(3) :896
Green TP, Mirkin BL. Prevention of cyclophosphamide-inducedantidiuresisbvfurrysemideinfusion. ClinPharmacolTher 1981;29 (5) :634.
Slavin RE, Millan JC, Mullins GM. Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol 1975;6(6) :693.
Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin oncol 1982;9(4):2
Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity follomng the treatment of pediatric patients with ifosfamide/mesna.JClinOncol 1986;4(8):1253
Pratt CB, Meyer WII, Jenkins], et al. Ifosfamide, Fanconi'ssyndrome, andrickets. J clinoncol 1991;9(8):1495
Boddy AV, Yule SM, WyJJie R, et al. Intrasubjectvariation in children of ifosfamidepharrnacokåncticsandmecaj)0jisjJ) (lucingrepeatedaduuinistvation. CancerChemotherpharmacol 1996;38(2):147
Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR. Pharmacokinetics, clinicaleffect of ifosfamide in breast cancer patients. Eur / Cancer1995;1:69
Cutter J, Wasserman LR, Martz G, et al. Theuse of low-doseprednisoneandthetreatment of poor-risk patientswith multiple myeloma. Med Pediatr Oncol 1975;1(3):207
Vesole DH, Crowley IJ, Catchatourian R, et al. High-dose melphalan withtation for refractory multiple myeloma: results of a southwestoncologygrouptrial. J ClinOncol 1999;17 (7):2173.
Norda A, Loos U, Sastry M, Goehl J, Hohenberger W. Pharmacokinetics of isolatedlimbperfusion. CancerChemotherPharmacol 1999;43 (1):35.
Goldenberg GJ, Lee M, Lam HY, Begleiter A. Evidenceforcarrier-mediatedmelphalanby L5178Y lymphoblasts in vitro. CancerRes 1977;37 (3):755
Begleiter A, Lam HY, Grover J, Froese E, Goldenberg GJ. Evidenceforactivephalanby two amino acidcarriers in L5178Y lymphoblasts in vitro. CancerRes 1979;39(1):353
Vistica DT, Rabon A, Rabinovitz M. Amino acidconferredprotectionagainstcomparison of amino acidswhichreducemelphalantoxicitytomurine bone sor cells (CFU-C) andmurine L1210 leukemiacells. ResCommunChemPathol 1979;23(1):171.
Groothuis DR, Lippitz BE, Fekete I, et al. Theeffect of an amino the rate of melphalan entry into brain and xenotransplanted glioma. 1992;52(20):5590.
Pallante SL, Fenselau C, Mennel RG, et al. Quantitationbygas cal ionization-massspectrometry of phenylalaninemustard in plasma of Res 1980;40 (7) :2268.
Hersh MR, Ludden TM, Kuhn JG, Knight WA 3rd. Pharmacokinetics of highdosemelphalan. Invest New Drugs 1983;1 (4):331.
Pinguet F, Martel P, Fabbro M, et al.phalan in patients under going peripheral blood plantation. AnticancerRes 1997;17(1B):605.
Han T, Rai KR. Management of chroniclymphocytecAm 1990;4(2):431.
Portlock CS, Fischer DS, Cadman E, et al. High-dosepulsechlorambucil in advanced, low-gradenon-Hodgkin'slymphoma. CancerTreatRep 1987;71 (11):1029.
Branten AJW, Reichert LJM, Koene RAP, Wetzels JFM. Oral cyclophosphamideversuschlorambucil in thetreatment of patientswithmembranousnephropathyand renal insufficiency. QJM 1998;91 (5):359.
Alberts DS, Chang SY, Chen H-SG, Larcom BJ, Evans TL. Comparativepharmacokinetics of chlorambucilandmelphalan in man. RecentResultsCancerRes 1980;74:124.
Przepiorka D, Khouri I, Thall P, et al. Thiotepa, busulfanandcyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 1999;23(10):977.
Andrievsky GY, Sukhodub LF, Pyatigorskaya TL, et al. Direct observation of thealkylationproducts of deoxyguanosineand DNA byfast atom bombardmentmassspectrometry. BiolMassSpectrom 1991;20(11):665.
Cohen NA, Egorin MJ, Snyder SW, et al. Interaction of N,N',N"-triethylenethiophosphoramideand N,N',N"-triethylenephosphoramidewithcellular DNA. CancerRes 1991;51 (16):4360.
Chang TK, Chen G, Waxman DJ. Modulation of thiotepaantitumoractivityinvivobyalter- 10 ation of livercytochrome P450-catalyzed drugmetabolism. J PharmacolExpTher 1995;274(1):270.
Kennedy MJ, Armstrong DK, Huelskamp AM, et al. Phase I andpharmacologicstudy of thealkylatingagentmodulatornovobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J ClinOncol 1995;13(5):1136.
Hussein AM, Petros WP, Ross M, et al. A phase I/II study of highdosecyclophosphamide, cisplatin, andthiotepafollowedbyautologous bone marrowandgranulocytecolonystimulatingfactor-primedperipheralbloodprogenitorcells in patients with advanced malignancies. CancerChemotherPharmacol 1996;37 (6):561.
Lyss AP, Luedke S, Einhorn L, Luedke DW, Raney M. Vindesineandmitomycin C in metastaticbreastcancer. A SoutheasternCancerStudyGroup Trial. Oncology 1989;46 (6):357.
Hong RL, Sheen TS, Ko JY, et al. Inductionwithmitomycin C, doxorubicin, cisplatinandmaintenancewithweekly 5-fluorouracil, leucovorinfortreatment of metastaticnasopharyngealcarcinoma: a phase II study. Br J Cancer 1999;80 (12):1962.
Arbuck SG, Silk Y, Douglass HO Jr, et al. A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, andleucovorin in advancedgastriccarcinoma. Cancer 1990;65 (11):2442.
Borowy-Borowski H, Lipman R, Chowdary D, Tomasz M. Duplex oligo deoxyribonucleotides cross-linked by mitomycin C at a single site: synthesis, properties, andcross-link reversibility. Biochemistry 1990;29 (12):2992.
Tomasz M, Lipman R, Chowdary D, et al. Isolationandstructure of a covalentcross-link adductbetweenmitomycin C and DNA. Science 1987;235 (4793):1204.
Rink SM, Lipman R, Alley SC, Hopkins PH, Tomasz M. Bending of DNA bythemitomycin C-induced, GpGintrastrandcross-link. ChemResToxicol 1996;9(2):382.
denHartigh J, McVie JG, vanOort WJ, Pinedo HM. Pharmacokinetics of mitomycin C in humans. CancerRes 1983;43(10):5017.
Institoris E, Tamas J. Alkylationby 1,2:5,6-dianhydrogalactitol of deoxyribonucleicacidandguanosine. Biochem / 1980;185 (3):659.
Haas CD, Baker L, Thigpen T. Phase II evaluation of dianhydrogalactitol in lungcancer: a SouthwestOncologyGroupStudy. CancerTreatRep 1981;65 (1): 115.
Edmonson JH, Frytak S, Letendre L, Kvols LK, Eagan RT. Phase II evaluation of dianhydrogalactitol in advancedheadandneckcarcinomas. CancerTreatRep 1979;63(11):2081.
Levin VA, Edwards MS, Gutin PH, et al. Phase II evaluation of dibromodulcitol in thetreatment of recurrentmedulloblastoma, ependymoma,andmalignantastrocytoma. JNeurosurg 1984;61 (6):1063.
Nguyen HN, Nordqvist SR. Chemotherapy of advancedandrecurrentcervicalcarcinoma. Semin SurgOncol 1999;16(3):247.
Horvath IP, Csetenyi J, Kerpel-Fronius S, et al. Pharmacokineticsandmetabolism of dianhydrogalactitol DAG in patients: a comparisonwiththehumandisposition of dibromodulcitol DBD. Eur / CancerClinOncol 1986;22(2):163.
Kelley SL, Peters WP, Andersen J, et al. Pharmacokinetics of dibromodulcitol in humans: a phase I study. J ClinOncol 1986;4(5):753.
Hartley JA, Berardini MD, Souhami RL. An agarose gel methodforthedetermination of DNA interstrandcross-linkingapplicabletothemeasurement of the rate of total and "second-arm" cross-link reactions. Anal Biochem 1991;193(1):131.
Streeper RT, Cotter RJ, Colvin ME, Hilton J, Colvin OM. Molecularpharmacology of hepsulfam, NSC 3296801: identification of alkylatednucleosides, alkylation site, and site of DNA cross-linking. CancerRes 1995;55 (7):1491.
Haddow A, Timmis GM. Myeleran in chronicmyeloidleukemia-chemicalconstitutionandbiologicalaction. Lancet 1953;1:207.
Hehlmann R, Heimpel H, Hasford J, et al. Randomizedcomparison of busulfanandhydroxyurea in chronicmyelogenousleukemia: prolongation of survivalbyhydroxyurea. TheGerman CML StudyGroup. Blood 1993;82(2):398.
Ohnishi K, Tomonaga M, Kamada N, et al. A longterm follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. LeukRes 1998;22(9):779.
Nevill TJ, Barnett MK, Klingemann HG, et al. Regimen-relatedtoxicity of a busulfancyclophosphamideconditioningregimen in 70 patientsundergoingallogeneic bone marrowtransplantation. J ClinOncol 1991;9(7):1224.
Santos GW. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia-a review. LeukLymph1993;1:201.
Chao NJ, Stein AS, Long GD, et al. Busulfan/etoposide-initialexperiencewith a newpreparatoryregimenforautologous bone marrowtransplantation in patientswithacutenonlymphoblasticleukemia. Blood 1993;81 (2):319.
Elson LA. Hematologiceffects of thealkylatingagents. Ann NY AcadSci1958;68:826.
Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlationwithveno-occlusivedisease in patientsundergoing bone marrowtransplantation. CancerChemotherPharmacol 1989;25 (1):55.
Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusivedisease of theliverfollowing bone marrowtransplantation. Transplantation 1987;44(6):778.
Leiter J, Schneiderman MA. Screening data fromtheCancerChemotherapyNational Service Center ScreeningLaboratories. CancerRes 1959;19(2):31.
Johnston TP, McCaleb GS, Montgomery JA. Thesynthesis of antineoplasticagents: XXXII. N-nitrosoureas. / MedChem1963;6:669.
Montgomery JA. Chemistryandstructure-activitystudies of thenitrosoureas. CancerTreatRep 1976;60 (6):651.
SchabelFMJr.Nitrosoureas: a review of experimental antitumor activity. CancerTreatRep 1976;60 (6) :665.
Schepartz SA. Earlyhistoryanddevelopment of thenitrosoureas. CancerTreatRep 1976;60(6):647.
Kohn KW. Interstrandcross-linking of DNA by 1,3-bis (2-chloroethyl)-1-nitrosourea andother 1-(2-haloethyl)-1-nitrosoureas. CancerRes 1977;37(5):1450
Colvin M, Brundrett RB, Cowens W, Jardine I, LudlumDB. A chemicalbasisfortheantitumoractivity of chloroethylnitrosoureas. BiochemPharmacol 1976;25 (6):695.
Tong WP, Kirk MC, LudlumDB.Mechanism of action of thenitrosoureas: V. Formation of O6-(2-fluoroethyl) guanineanditsprobable role in thecross-linking of deoxyribonucleicacid. BiochemPharmacol 1983;32(13):2011.
Fischhaber PL, Gall AS, Duncan JA, Hopkins PB. Direct demonstration in syntheticoligonucleotidesthatN,N'-bis (2-chloroethyl)-nitrosoureacross-links N-1 of deoxyguanosineto N-3 of deoxycytidine on oppositestrands of duplex DNA. CancerRes 1999;59(17):4363.
Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/ orradiotherapy in thetreatment of anaplasticgliomas. A cooperativeclinicaltrial. J Neurosurg 1978;49(3):333.
Blade J, Rozman C, Montserrat E, et al. Treatment of alkylatingresistant multiple myelomawithvincristine, BCNU, doxorubicinandprednisone (VBAP). Eur J CancerClinOncol 1986;22 (10):1193.
Eder JP, Antman K, Peters W, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J ClinOncol 1986;4(11):1592.
Garfield J, Dayan AD, Weller RO. Post operative intracavitary chemotherapy of malignantsupratentorialastrocytomasusing BCNU. ClinOncol 1975;1 (3):213.
Brem H, Piantadosi S, Burger PC, et al. Placebo-controlledtrial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345 (8956):1008.
Paleologos NA, Macdonald DR, Vick NA, Cairncross JG. Neoadjuvantprocarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 1999;53(5):1141.
Prados MD, Scott C, Curran WJ, et al. Procarbazine, lomustine, andvincristine (PCV) chemotherapy for anaplasticastrocytoma: a retrospectivereview of Radiation Therapy Oncology Group protocols comparing survival with carmustineor PCV adjuvantchemotherapy. J ClinOncol 1999;17 (11):3389.
Clark JL, Barcewicz P, Nava HR, Goodwin PS, Douglass HO Jr. Adjuvant 5-FU and MeCCNU improves survival following curative gastrectomy for adenocarcinoma. AmSurg 1990;56(7):423
Paccapelo A, Piana C, Rychlicki F, et al. Treatment of malignantgliomas: a newapproach.Tumori 1998;84(5):529.
Arita N, Ushio Y, Hayakawa T, et al. Intrathecal ACNU-a new therapeutic approach against malignant leptomeningeal tumors. J Neurooncol 1988;6(3):221.
Alberts DS, Durie BG, Salmon SE. Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse. Lancet 1976;1 (7966):926.
Levin VA, Hoffman W, Weinkam RJ. Pharmacokinetics of BCNU in man: a preliminaryomostudy of 20 patients. CancerTreatRep 1305;62 (9):1305.
Meisenberg BR, Ross M, Vredenburgh IJ, et al. Randomizedtrial of high-dose chemotherapy with autologous bone marrowsupport as adjuvanttherapyforhigh-risk, multinode-positivemalignant melanoma. J NatlCancerInst 1993;85 (13):1080.
Henner WD, Peters WP, Eder JP, et al. Pharmacokineticsandimmediateeffects of highdosecarmustine in man. CancerTreatRep 1986;70 (7):877.
Levin VA, Stearns J, Byrd A, Finn A, Weinkam RJ. Theeffect of phenobarbitalpretreatment on theantitumoractivity of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J PharmacolExpTher 1979;208 (1):1.
Lee FY, Workman P, Roberts JT, Bleehen NM. Clinicalpharmacokinetics of oral CCNU (lomustine). CancerChemotherPharmacol 1985;14(2):125.
DeVita VT, Carbone PP, Owens AH Jr, et al. Clinicaltrialswith 1,3-Bis (2-chloroethyl)-1nitrosourea, NSC-409962. CancerRes1965;25:1876.
Toth B. Syntheticandnaturallyoccurringhydrazines as possible cancer causative agents. CancerRes 1975;35 (12):3693.
Silverstein R, Bhatia P, Svoboda DJ. Effect of hydrazinesulfate on glucose-regulatingenzymes in the normal andcancerousrat. Immunopharmacology 1989;17(1):37.
Gold J. Use of hydrazinesulfate in terminal andpreterminalcancerpatients: results of investigationalnewdrug (IND) study in 84 evaluablepatients. Oncology 1975;32(1):1.
Herndon JE, Fleishman S, Kosty MP, Green MR. A longitudinalstudy of quality of life in advancednon-smallcelllungcancer-CancerandLeukemiaGroup B 8931. Control ClinTrials 1997;18(4):286.
Kamradt JM, Pienta KJ. Theeffect of hydrazinesulfate on prostatecancergrowth. OncolRep 1998;5 (4):919.
Spies SK, Snyman HW. Procarbazine (Natulan) in thetreatment of Hodgkin'sdiseaseandotherlymphomas. S AfrMed J 1966;40 (44):1061.
Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8year results of theintergrouptrial. J ClinOncol 1998;16(1):19.
Brandes AA, Ermani M, Turazzi S, et al. Procarbazineandhigh-dosetamoxifenas a secondlineregimen in recurrenthigh-gradegliomas: a phase II study. J ClinOncol 1999;17(2):645.
Fink D, Aebi S, Howell SB. The role of DNA mismatchrepair in drugresistance. ClinCancerRes 1998;4(1) :1.
Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiformexenograft. CancerRes 1997;57(14):2933.
Bianchini F, Weiderpass E, Kyrtopoulos S, et al. Detection of DNA methylationadducts in Hodgkin's disease patients treated with procarbazine. Biomarkers 1996;1 (4):226.
Erikson JM, Tweedie DJ, Ducore JM, Prough RA. Cytotoxicityand DNA damage caused by the azoxymetabolites of procarbazine in L1210 tumorcells. CancerRes 1989;49(1):127.
Swaffar DS, Horstman MG, Jaw JY, et al. Methylazoxyprocarbazine, theactive metabolite responsiblefortheanticanceractivity of procarbazineagainst L1210 leukemia. CancerRes 1989;49(9):2442.
Massie MJ, Holland JC. Diagnosisandtreatment of depression in thecancerpatient. J Clin 138. PfefferbaumPsychiatry 1984;45 B, Pack (3):25.R, vanEys J. Monoamine oxidaseinhibitortoxicity. J AmAcad Child AdolescPsychiatry 1989;28(6):954.
Farina P, Benfenati E, Reginato R, et al. Metabolism of theanticanceragent 1-(4acetylphenyl)-3,3-dimethyltriazene. BiomedMassSpectrom 1983;10(8):485.
Skibba JL, Beal DD, Ramirez G, Bryan GT. N-demethylationtheantineoplastic agent4(5)(3,3-dimethyl-1-triazeno) imidazole-5(4)-carboxamidebyratsand man. CancerRes 1970;30(1):147.
Skibba JL, Beal DD, Ramirez G, Bryan GT. N-demethylationtheantineoplastic agent4(5)(3,3-dimethyl-1-triazeno) imidazole-5(4)-carboxamidebyratsand man. CancerRes 1970;30(1):147.
Vaughan K, Tang Y, Llanos G, et al. Studies of themode of action of antitumortriazenesandtriazines: 6. 1-Aryl-3-(hydroxymethyl)-3-methyltriazenes: synthesis, chemistry, andantitumorproperties. J MedChem 1984;27 (3):357.
DeVita VT, Mauch PM, Harris NL. Hodgkin'sdisease. In: DeVita VT Jr, Hellman S, Rosenberg S, eds. Cancer: principles&practice of oncology. Philadelphia: Lippincott-Raven Publishers,1997:2268.
Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazineversusdacarbazinewith interferon alpha-2b versus dacarbazine with tamoxifen ersus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Groupstudy. J ClinOncol 1998;16(5):1743.
Lowe PR, Sansom CE, Schwalbe CH, Stevens MF, Clark AS. Antitumor imidazotetrazines:25. Crystalstructure of 8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC. J MedChem 1992;35 (18):3377.
Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the anti tumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33(31):9045.
Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in childrenandadolescentsOncol 1998;16(9):3037.withrecurrentsolidtumors-a report from the Children's Cancer Group. J Clinoncol 1998;16(9):3037
Hammond LA, Eckardt JR, Baker SD, et al. Phase I andpharmacokineticstudy of temozolomide on a daily-for-5-days schedule in patientswithadvancedsolidmalignancies. J ClinOncol 1999;17(8):2604.
Paulsenblastoma F, Hoffmann multiforme: W, Becker ifosfamideG, et versus al. Chemotherapytemozolomide. inthe J treatmentCancerofResrecurrentClin Oncolglio1999;125 (7):411.
Newlands ES, Oreilly SM, Glaser MG, et al. TheCharing Cross Hospitalexperiencewithtemozolomide in patientswithgliomas. Eur J Cancer1996;13:2236.
Woll PJ, Judson I, Lee SM, et al. Temozolomide in adultpatientswithadvancedsofttissuesarcoma: a phase II study of the EORTC SoftTissueand Bone SarcomaGroup.EurJCancer 1999;35 (3):410
Moore MJ, untreatedFeld R, pancreaticHedley D, cancer. Oza A, InvestSiu LL. New A DrugsPhase 1998;16(1):77
Breithaupt H, Dammann A, Aigner K. Pharmacokinetics (AIC) following of dacarbazinedifferentdose (DTIC) schedules.andits metabolite5-aminoimidazole-4-carboxamide CancerChemotherPharmacol 1982;9(2):103.
Adkins DR, Irvin R, Kuhn J, et al. A phase I clinicalandpharmacological profile of dacarbazinewithautologous bone marrowtransplantation in patientswithsolidtumors. Invest New Drugs 1993;11 (2):169.
Reid JM, Stevens DC, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl) imidazole-4-carboximide followingadministration of temozolomidetopatientswithadvancedcancer. ClinCancerRes 1997;3(12):2393.
Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, andexcretion of 14C-temozolomide following oral administrationtopatientswithadvancedcancer. ClinCancerRes 1999;5(2):309.
